Evaluating the Impact of COVID-19 (Coronavirus) on Research in Care Homes

November 9, 2022 updated by: The Royal Wolverhampton Hospitals NHS Trust

Evaluating the Impact of COVID-19 on Research in Care Homes

During the COVID-19 (corona virus) pandemic the research arena has had to rapidly adapt and change in order to facilitate and deliver research. The UK (United Kingdom) government and Public Health England have stressed the importance of such research to find solutions to treating, preventing and stopping the spread of COVID-19. Due to national and international 'lock down restrictions' delivering research in care home settings has become even more challenging. The adaptations to conducting consultations have relied heavily on the use of technology, for example video calling, telephone, email, and teleconferencing. It is suggested that the use of technology in care home settings is already a barrier to effective research delivery.

Nevertheless, as care home residents are a vulnerable group, it is critical to include these groups in research in order to enable improved and evidence-based care and their access to new and emerging treatments.

This study aims to assess the opinions and experiences of key stakeholders to identify barriers, and enable better facilitation of research in these settings during and post pandemic.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This two phase project will use a mixed methodology.

Phase one will involve mixed methods surveys. One will be completed by care home residents and the other will be completed by research delivery staff and care home staff.

Phase two will involve qualitative interviews with each of these groups to enable better insight into their views and opinions on research in this area.

Study Type

Observational

Enrollment (Actual)

7

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Wolverhampton, United Kingdom
        • The Royal Wolverhampton NHS Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Any staff member working/volunteering in a care home, research staff, residents of care homes, relatives of care home residents, all across the West Midlands are eligible to take part in this research project.

Description

Inclusion Criteria:

  • Any resident of a care home in the West Midlands
  • Any relative/friend of a care home resident in the West Midlands
  • Any staff member or volunteer working in care home in the West Midlands
  • Any researcher undertaking research in a care home in the West Midlands (during the pandemic or proposed during the pandemic period)

Exclusion Criteria:

  • Individuals who are unable to give Informed Consent
  • Individuals who lack capacity

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Online Survey
Online survey
Online survey
Interviews
Interview

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acceptability of vaccine studies in the care home setting through feedback questionnaire with loose themes and no unique measurements.
Time Frame: 6 months
To inform the design and delivery of vaccine studies in the care home setting, ensuring they are acceptable by key stakeholders
6 months
Acceptability of vaccine studies in the care home setting through feedback interview with loose themes and no unique measurements
Time Frame: 6 months
To inform the design and delivery of vaccine studies in the care home setting, ensuring they are acceptable by key stakeholders
6 months
Acceptability of new ways of delivering research through explorative interview with loose themes and no unique measurements
Time Frame: 6 months
To inform and assess the acceptability of new ways of delivering research in care home settings, guiding changes and implementation of new ways of working moving forward
6 months
Acceptability of new ways of delivering research through explorative questionnaire with loose themes and no unique measurements
Time Frame: 6 months
To inform and assess the acceptability of new ways of delivering research in care home settings, guiding changes and implementation of new ways of working moving forward
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kelly Hard, National Institute for Health Research, United Kingdom

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 14, 2021

Primary Completion (ACTUAL)

July 30, 2022

Study Completion (ACTUAL)

July 30, 2022

Study Registration Dates

First Submitted

January 18, 2021

First Submitted That Met QC Criteria

January 18, 2021

First Posted (ACTUAL)

January 20, 2021

Study Record Updates

Last Update Posted (ACTUAL)

November 10, 2022

Last Update Submitted That Met QC Criteria

November 9, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

Clinical Trials on Interview

Subscribe